Detalhe da pesquisa
1.
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial.
Lancet
; 392(10162): 2367-2377, 2018 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30360969
2.
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial.
Lancet
; 392(10162): 2378-2387, 2018 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30360970
3.
VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia.
Leukemia
; 37(2): 326-338, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36376377
4.
First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy.
Clin Cancer Res
; 28(7): 1285-1293, 2022 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35046056
5.
Pten and the brain: sizing up social interaction.
Neuron
; 50(3): 343-5, 2006 May 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-16675386
6.
Hoxb8 is required for normal grooming behavior in mice.
Neuron
; 33(1): 23-34, 2002 Jan 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-11779477